GCM
Graham Capital Management Portfolio holdings
AUM
$3.28B
1-Year Return
7.17%
This Quarter Return
-1%
1 Year Return
+7.17%
3 Year Return
+21.95%
5 Year Return
+42.01%
10 Year Return
+61.8%
AUM
$2.9B
AUM Growth
-$616M
(-18%)
Cap. Flow
-$1.89B
Cap. Flow
% of AUM
-65.24%
Top 10 Holdings %
Top 10 Hldgs %
35.52%
Holding
1,434
New
418
Increased
270
Reduced
261
Closed
442
Top Buys
| 1 |
Strategy Inc Common Stock Class A
MSTR
|
+$31.6M |
| 2 |
HES
Hess
HES
|
+$16.8M |
| 3 |
Coca-Cola
KO
|
+$16M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$13.9M |
| 5 |
Boston Scientific
BSX
|
+$13.8M |
Top Sells
| 1 |
Amazon
AMZN
|
+$27.6M |
| 2 |
Microsoft
MSFT
|
+$26.9M |
| 3 |
Dollar General
DG
|
+$22.7M |
| 4 |
Uber
UBER
|
+$21.3M |
| 5 |
NVIDIA
NVDA
|
+$19.1M |
Sector Composition
| 1 | Technology | 10.64% |
| 2 | Industrials | 7.41% |
| 3 | Financials | 6.89% |
| 4 | Consumer Discretionary | 5.06% |
| 5 | Healthcare | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
901
Potbelly
PBPB
$514M
| $94.5K | ﹤0.01% |
+11,768
| New | +$94.5K |
|
902
uniQure
QURE
$959M
| $93.4K | ﹤0.01% |
+20,858
| New | +$93.4K |
|
903
Cardiff Oncology
CRDF
$136M
| $93.1K | ﹤0.01% |
+41,922
| New | +$93.1K |
|
|
SRG
904
Seritage Growth Properties
SRG
$251M
| $90K | ﹤0.01% |
+19,262
| New | +$90K |
|
|
FNA
905
DELISTED
Paragon 28, Inc.
FNA
| $88.3K | ﹤0.01% |
+12,910
| New | +$88.3K |
|
906
Codexis
CDXS
$219M
| $87.8K | ﹤0.01% |
+28,326
| New | +$87.8K |
|
|
BHR
907
Braemar Hotels & Resorts
BHR
$199M
| $84.5K | ﹤0.01% |
33,136
-9,009
| -21% | -$23K |
|
908
Alta Equipment Group
ALTG
$246M
| $83.8K | ﹤0.01% |
+10,420
| New | +$83.8K |
|
909
Adverum Biotechnologies
ADVM
$69.5M
| $80.8K | ﹤0.01% |
+11,782
| New | +$80.8K |
|
910
FibroGen
FGEN
$46.5M
| $80.3K | ﹤0.01% |
+3,599
| New | +$80.3K |
|
|
ONL
911
Orion Office REIT
ONL
$165M
| $79.1K | ﹤0.01% |
22,046
-14,302
| -39% | -$51.3K |
|
912
Heron Therapeutics
HRTX
$195M
| $78.1K | ﹤0.01% |
+22,304
| New | +$78.1K |
|
913
Douglas Elliman
DOUG
$230M
| $76.1K | ﹤0.01% |
65,602
+26,720
| +69% | +$31K |
|
914
Cerus
CERS
$226M
| $71.9K | ﹤0.01% |
40,873
-17,576
| -30% | -$30.9K |
|
915
Definitive Healthcare
DH
$414M
| $69.9K | ﹤0.01% |
+12,798
| New | +$69.9K |
|
916
BARK
BARK
$147M
| $69.8K | ﹤0.01% |
38,586
+2,124
| +6% | +$3.84K |
|
917
Kodiak Sciences
KOD
$514M
| $69.8K | ﹤0.01% |
+29,682
| New | +$69.8K |
|
918
Angi Inc
ANGI
$769M
| $69.3K | ﹤0.01% |
+3,612
| New | +$69.3K |
|
919
Nerdy
NRDY
$157M
| $68.8K | ﹤0.01% |
+41,225
| New | +$68.8K |
|
920
Adicet Bio
ACET
$66.9M
| $66.8K | ﹤0.01% |
55,184
+28,894
| +110% | +$35K |
|
921
Invivyd
IVVD
$270M
| $65.4K | ﹤0.01% |
59,469
+42,079
| +242% | +$46.3K |
|
922
AngioDynamics
ANGO
$445M
| $65.1K | ﹤0.01% |
+10,766
| New | +$65.1K |
|
923
Marqeta
MQ
$2.64B
| $64.8K | ﹤0.01% |
+11,826
| New | +$64.8K |
|
924
Nokia
NOK
$24.6B
| $63.8K | ﹤0.01% |
+16,870
| New | +$63.8K |
|
925
Conduent
CNDT
$442M
| $63.7K | ﹤0.01% |
+19,528
| New | +$63.7K |
|